GlassScriptPhysician profile
Ruben Ruiz
NPI 1912901471
$2,882.25
in general payments reported to CMS, 2019-2025
21 companies · $519 in 2025
The $519 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $963 · 2020: $144 · 2021: $75.05 · 2022: $305 · 2023: $426 · 2024: $451 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,395.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $588.85 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $457.67 | 2022-2025 | |
| Lilly USA, LLC | $303.27 | 2022-2025 | Zepbound, Jardiance |
| Amgen INC. | $148.70 | 2024-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $140.79 | 2020-2023 | Xarelto |
| Allergan, INC. | $138.50 | 2019-2021 | |
| Eisai INC. | $125.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $114.89 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $113.89 | 2019-2025 | Farxiga, Breztri |
| Sumitomo Pharma America, INC. | $110.11 | 2024-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $110.00 | 2019 | |
| Ironwood Pharmaceuticals, INC | $102.53 | 2024 | |
| Glaxosmithkline, LLC. | $93.60 | 2022-2025 | Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.68 | 2019 | |
| Pfizer INC. | $68.54 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $60.95 | 2024-2025 | |
| Pbg Puerto Rico LLC | $29.95 | 2023 | |
| Novo Nordisk INC | $28.97 | 2019-2020 | |
| Abbott Laboratories | $28.91 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.70 | 2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $18.75 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruben Ruiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.